Introduction: Fuzhou Adora Pharmaceutical Co., Ltd. was founded in 1994, located in Fuzhou railway station 2 kilometers east, covers an area of 20 acres, convenient transportation. The green area of the factory has reached 50%, with a beautiful and pollution-free environment. The company has its own specialized production base of medicinal herbs, which provides pollution-free medicinal raw materials for the products. Our company is a high-tech enterprise in Fujian Province. Among the existing staff, more than 50% are graduates from universities and junior colleges. Middle and senior technicians account for 30%. Plant layout and production line construction in accordance with the "Good Manufacturing Practice" (GMP) requirements, the workshop will be strictly separated from people, logistics, the application of central air-conditioning purification system, cleanliness to more than 100,000 standard, has been able to produce punch, capsule two dosage forms. The laboratory of the plant has a set of advanced analytical instruments and is equipped with graduates of the University of Pharmacy, which can meet the needs of comprehensive quality control of the whole plant's drug production process to ensure the quality. The main product of the company is the anti-cancer Chinese medicine Andolin Capsule. This drug is a national new drug approved by the Ministry of Health, and the formula is confidential. It has been listed as "National Essential Drug" by the State Drug Administration. In 1997, the State Pharmaceutical Administration selected 11 new drugs with good research progress from 382 new drug researches financed in the past 10 years and awarded them "New Drug Development Prize", of which Andolin was one of them; in 1998, it was honored by the State Economic and Trade Commission as one of the "New Drug Development Prizes". In 1998, Andolin was honored by the State Economic and Trade Commission as "National Key New Product", evaluated as "International Advanced Level, Substitute for Imported, Anti-cancer and Cancer Prevention"; In 1999, Andolin was recommended by the Science and Technology Commission of Fujian Province and the Economic Commission of Fujian Province to participate in the "First China High-tech Products Fair" on behalf of Fujian Province. In 1999, it was recommended by Fujian Provincial Science and Technology Commission and Economic Commission to represent Fujian Province to participate in the "The First China High-tech Products Fair", and was awarded as "Outstanding Project of Science and Education Achievement of Fujian Province in 50 Years of the Founding of the People's Republic of China", and was listed as one of the "High-tech Industrialization and Promotion Technological Projects" by the State Planning Commission in 2001. Andolin Capsules have been listed in the basic medical insurance drug catalog of Fujian Province. Andolin Capsules have now entered into some markets in China, such as Beijing, Fujian, Guangdong, etc.. In Beijing, there are some three-A hospitals, such as 301 Hospital, Cancer Hospital, Union Hospital, Military General Hospital and Beijing Children's Hospital; in Shandong, Zhejiang, Jiangxi and other provinces and cities, there are tumor hospitals; in Fujian Province, there are the Provincial Cancer Hospital, the Provincial Hospital, the First Affiliated Hospital of the University of Medical Science and Technology, the Union Hospital, the Fuzhou General Hospital of the Nanjing Military Command, and other three-A hospitals. The product is conducting national investment and gradually enter the international market, now has entered Singapore and Indonesia and other countries; has passed the U.S. FDA review, in the name of health care and nutritional products to enter the U.S. market. Due to the strong anti-radiation effect found in the pharmacodynamic study, Andolin Capsule was approved by the State Drug Administration in 1999 to carry out the clinical trial of five types of new drugs to expand the anti-radiation indications, and was approved by the State Drug Administration in July 2001 to become the first anti-radiation traditional Chinese medicine in China. Its development prospects and market potential is huge. Because radiation damage is currently a major threat to people's health, pilots, air hostesses, frequent flyers are subject to the risk of radiation at high altitude, commonly used computers, cell phones also have the problem of radiation, the United Nations Health Organization and the China Consumers Association have called attention to the hazards of electromagnetic radiation, indicating that Andolin will bring a new gospel to people's health. The company integrates research, development and production, and takes the road of innovation. The main developer of Andolin capsules, researcher Liu Zhongzhu, the chairman of the company, is a middle-aged and young expert with outstanding contributions honored by the Ministry of Personnel of the People's Republic of China, the former president of the Fujian Academy of Agricultural Sciences (1985-1996), and the director of the Biotechnology Research Center of the Provincial Academy of Agricultural Sciences. The company has made great development in tissue culture technology, and has cultivated some rare plants for medicinal use, such as the histocultured seedlings of Trichosanthes and Goldenseal, and found a new plant rich in Trichosanthes esterine, which has also been successfully produced by factory production of tissue culture, which will open up a new way for factory production of traditional Chinese medicines. Promising progress has been made in the research of ultramicro powder.
Legal representative: Liu Rundong
Established: 1994-11-09
Registered capital: 600,000 U.S. dollars
Industrial and Commercial Registration No.: 350100400002119
Enterprise type: Limited Liability Company (Taiwan, Hong Kong, Macao, and Domestic Joint Venture)
Corporate address: Jin'an district, Fuzhou city No.8 Guishan Road, Xindian